Table 1 Demographic and clinical characteristics of groups
From: The miRNA 196a2 rs11614913 variant has prognostic impact on Turkish patients with multiple myeloma
Patient group | Control group | |||
|---|---|---|---|---|
Median | N:200 (%) | N:200 (%) | ||
Age | 56 (28-82) | 53 (22-68) | ||
Gender | Female/Male | 91/109 (45.5/54.5) | 99/101 (49.5/50.5) | |
Ig subtypes | κ/λ | 110/60 (64.7/35.3) | ||
G/A | 112/30 (65.2/17.4) | |||
Light Chain | 30 (17.4) | |||
Stages (Salmon-Durie) | II/III | 53/117 (31/69) | ||
A/B | 129/41 (76/24) | |||
ISS | I | 52 (30.4) | ||
II/III | 44/75 (25.7/43.9) | |||
ECOG | >1 | 32/179 (17.9) | ||
Hemoglobin | gr/dl | 10.3 (5.9-15.5) | ||
White blood cell count | /μl | 6985 (5900-17,000) | ||
Platelet count | 103/μl | 170 (28-788) | ||
C-reactive protein | mg/dl | 8.8 (2.1-352) | ||
LDH | IU/l | 203 (93-1037) | ||
β2-microglobulin | mg/l | 5.0 (1.5-47) | ||
Albumin | g/l | 3.5 (1.6-5.1) | ||
Treatment | VCd, OHKHT, Rd | 156 (78) | ||
VCd ± Rd | 44 (22) | |||
Cytogenetic results (n:190) | Normal (XX, XY) | 179 | ||
13q | 2 | |||
Monosomy (X, 14-22) | 2 | |||
Hyper/diploidy | 2 + 2 | |||
t (4;11) | 1 | |||
t (4;14) | 1 | |||
Trisomy 7 | 1 | |||
OS (5 years) % | 71 | |||
PFS (months)a | 43.8 | |||
Mortality | 47 (26.5) | |||
Follow-up period a(month) | 30 (4.8-155) | |||